/PRNewswire/ YishengBio Co., Ltd (to be renamed as YS Biopharma Co., Ltd., and herein referred to as "YS Biopharma"), a global biopharmaceutical company.
Business Combination to deliver approximately $36 million of gross proceeds YS Biopharma expects to close the Business Combination on March 16, 2023 YS Biopharma Ordinary Shares and YS Biopharma Warrants expected to begin trading on the Nasdaq on March 17, 2023 under the symbols "YS" and "YSBPW," respectively NEW YORK, March 15, 2023 /PRNewswire/ YishengBio Co., Ltd.
Extraordinary general meeting of Summit Healthcare Acquisition Corp. s shareholders to be held on March 1, 2023 at 9:00 a.m. Eastern Time YS Biopharma is a.
Transaction values YS Biopharma at pre-money equity value of $834 million Certain investors ("Forward Purchase Investors") are expected to invest $30 million.
Transaction values YS Biopharma at pre-money equity value of $834 million Certain investors ("Forward Purchase Investors") are expected to invest $30 million.